<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-3-81-85</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>Применение ингибитора интерлейкина 1 у пациентки с атипичным течением периодической болезни</article-title><trans-title-group xml:lang="en"><trans-title>The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максим Сергеевич Елисеев</p><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Maxim Sergeevich Eliseev</p><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5394-7869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Желябина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhelyabina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3667-722X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8777-7597</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чикина</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Chikina</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8764-9202</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курбанмагомедов</surname><given-names>М. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurbanmagomedov</surname><given-names>M. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9755-5760</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Урумова</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Urumova</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6906-0621</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3689-431X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Салугина</surname><given-names>С. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Salugina</surname><given-names>S. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2282-1745</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федоров</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorov</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1598-8360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p><p>Россия, 119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p><p>8, Trubetskaya St., Build. 2, Moscow 119991, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p><p>Россия, 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p><p>2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Department of rheumatology Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2021</year></pub-date><volume>15</volume><issue>3</issue><fpage>81</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., Желябина О.В., Новикова А.М., Чикина М.Н., Курбанмагомедов М.К., Урумова М.М., Николаева Е.В., Салугина С.О., Федоров Е.С., Насонов Е.Л., Лила А.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С., Желябина О.В., Новикова А.М., Чикина М.Н., Курбанмагомедов М.К., Урумова М.М., Николаева Е.В., Салугина С.О., Федоров Е.С., Насонов Е.Л., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S., Zhelyabina O.V., Novikova A.M., Chikina M.N., Kurbanmagomedov M.K., Urumova M.M., Nikolaeva E.V., Salugina S.O., Fedorov E.S., Nasonov E.L., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1153">https://mrj.ima-press.net/mrj/article/view/1153</self-uri><abstract><p>В статье представлено наблюдение периодической болезни (ПБ) у пациентки 35 лет, не имевшей наследственных и доказанных генетических факторов заболевания, которое характеризовалось атипичным течением с вариабельными по продолжительности и частоте приступами выраженной боли в животе и фебрильной лихорадки, повышением острофазовых показателей и неэффективностью приема колхицина. Дифференциальная диагностика проводилась с широким кругом состояний, сопровождающихся лихорадкой. В качестве диагностического маркера для подтверждения диагноза ПБ были использованы ежедневные подкожные инъекции ингибитора интерлейкина 1 (иИЛ1) в дозе 100 мг. В результате терапии были достигнуты быстрое, в течение нескольких часов после введения, купирование текущего приступа болезни, нормализация сывороточного уровня СРБ, в дальнейшем – полный контроль над заболеванием (отсутствие рецидивов). Наше наблюдение показывает, что положительный ответ на терапию иИЛ1 может служить диагностическим маркером ПБ.</p></abstract><trans-abstract xml:lang="en"><p>The article presents a case of periodic fever (PF) in a 35-year-old patient, who did not have hereditary and proven genetic factors of the disease, which was characterized by an atypical course with variable in duration and frequency severe abdominal pain and febrile fever attacks, increased acute phase reactants and ineffectiveness of colchicine intake. Differential diagnosis with a wide range of febrile conditions was performed. Daily subcutaneous therapy of interleukin 1 inhibitor (iIL1) at a dose of 100 mg was used as a diagnostic marker to confirm the diagnosis of PF. As a result of the therapy, a rapid (within a few hours after injection) relief of the current attack of the disease, normalization of serum CRP levels, and further complete control over the disease (no relapses) were achieved. Our observation shows that a positive response to iIL1 therapy can serve as a diagnostic marker of PF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>периодическая болезнь</kwd><kwd>ингибитор интерлейкина 1</kwd><kwd>колхицин</kwd><kwd>диагностика</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>periodic fever</kwd><kwd>interleukin 1 inhibitor</kwd><kwd>colchicine</kwd><kwd>diagnostics</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008 Jun;29(6):803-8. doi: 10.1002/humu.20720.</mixed-citation><mixed-citation xml:lang="en">Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008 Jun;29(6):803-8. doi: 10.1002/humu.20720.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Салугина СО, Федоров ЕС, Кузьмина НН. Современные подходы к диагностике, лечению и мониторингу пациентов с криопирин-ассоциированными периодическими синдромами (CAPS). Современная ревматология. 2016;10(2):4-11.</mixed-citation><mixed-citation xml:lang="en">Salugina SO, Fedorov ES, Kuz'mina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrinassociated periodic syndromes (CAPS). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2):4-11. (In Russ.). doi: 10.14412/1996-7012-2016-2-4-11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lalaoui N, Boyden SE, Oda H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature. 2020 Jan;577(7788):103-8. doi: 10.1038/s41586-019-1828-5. Epub 2019 Dec 11.</mixed-citation><mixed-citation xml:lang="en">Lalaoui N, Boyden SE, Oda H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature. 2020 Jan;577(7788):103-8. doi: 10.1038/s41586-019-1828-5. Epub 2019 Dec 11.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med. 2001 Dec 13; 345(24):1748-57. doi: 10.1056/NEJMra010200.</mixed-citation><mixed-citation xml:lang="en">Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med. 2001 Dec 13; 345(24):1748-57. doi: 10.1056/NEJMra010200.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015 May;74(5):799-805. doi: 10.1136/annrheumdis-2014-206580. Epub 2015 Jan 30.</mixed-citation><mixed-citation xml:lang="en">Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015 May;74(5):799-805. doi: 10.1136/annrheumdis-2014-206580. Epub 2015 Jan 30.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4): 395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4.</mixed-citation><mixed-citation xml:lang="en">Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4): 395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician. 2017 Oct;63(10):756-762.</mixed-citation><mixed-citation xml:lang="en">Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician. 2017 Oct;63(10):756-762.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean Fever. Acta Medica (Hradec Kralove). 2014;57(3):97-104. doi: 10.14712/18059694.2014.47.</mixed-citation><mixed-citation xml:lang="en">Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean Fever. Acta Medica (Hradec Kralove). 2014;57(3):97-104. doi: 10.14712/18059694.2014.47.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.</mixed-citation><mixed-citation xml:lang="en">Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.</mixed-citation><mixed-citation xml:lang="en">Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017 Apr;69(4):578-86. doi: 10.1002/acr.23120. Epub 2017 Mar 3.</mixed-citation><mixed-citation xml:lang="en">Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017 Apr;69(4):578-86. doi: 10.1002/acr.23120. Epub 2017 Mar 3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ozen S, Kone-Paut I, Gü l A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017 Aug;47(1):115-20. doi: 10.1016/j.semarthrit.2017.03.006. Epub 2017 Mar 20.</mixed-citation><mixed-citation xml:lang="en">Ozen S, Kone-Paut I, Gü l A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017 Aug;47(1):115-20. doi: 10.1016/j.semarthrit.2017.03.006. Epub 2017 Mar 20.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">http://fmf.igh.cnrs.fr/infevers/.</mixed-citation><mixed-citation xml:lang="en">http://fmf.igh.cnrs.fr/infevers/.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41. doi: 10.1136/annrheumdis-2014-206844. Epub 2015 Jan 27.</mixed-citation><mixed-citation xml:lang="en">Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41. doi: 10.1136/annrheumdis-2014-206844. Epub 2015 Jan 27.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009 Jun;60(6):1862-6. doi: 10.1002/art.24570.</mixed-citation><mixed-citation xml:lang="en">Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009 Jun;60(6):1862-6. doi: 10.1002/art.24570.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Chetrit E1, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009 Oct 15;61(10):1447-53. doi: 10.1002/art.24458.</mixed-citation><mixed-citation xml:lang="en">Ben-Chetrit E1, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009 Oct 15;61(10):1447-53. doi: 10.1002/art.24458.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Chetrit E, Ozdogan H. Nonresponse to colchicine in FMF — definition, causes and suggested solutions. Clin Exp Rheumatol. Jul-Aug 2008;26(4 Suppl 50): S49-51.</mixed-citation><mixed-citation xml:lang="en">Ben-Chetrit E, Ozdogan H. Nonresponse to colchicine in FMF — definition, causes and suggested solutions. Clin Exp Rheumatol. Jul-Aug 2008;26(4 Suppl 50): S49-51.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017 Apr;69(4):854-62. doi: 10.1002/art.39995.</mixed-citation><mixed-citation xml:lang="en">Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017 Apr;69(4):854-62. doi: 10.1002/art.39995.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gü l A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015 Sep 4;17(1):243. doi: 10.1186/s13075-015-0765-4.</mixed-citation><mixed-citation xml:lang="en">Gü l A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015 Sep 4;17(1):243. doi: 10.1186/s13075-015-0765-4.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sahin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicineresistant/ unresponsive familial Mediterranean fever. Adv Rheumatol. 2020 Jan 30;60(1):12. doi: 10.1186/s42358-020-0117-1.</mixed-citation><mixed-citation xml:lang="en">Sahin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicineresistant/ unresponsive familial Mediterranean fever. Adv Rheumatol. 2020 Jan 30;60(1):12. doi: 10.1186/s42358-020-0117-1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.</mixed-citation><mixed-citation xml:lang="en">Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hentgen V, Vinit C, Fayand A, Georgin- Lavialle S. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review. Front Immunol. 2020 May 28;11:971. doi: 10.3389/fimmu.2020.00971. eCollection 2020.</mixed-citation><mixed-citation xml:lang="en">Hentgen V, Vinit C, Fayand A, Georgin- Lavialle S. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review. Front Immunol. 2020 May 28;11:971. doi: 10.3389/fimmu.2020.00971. eCollection 2020.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
